[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577952":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":47,"collaborators":23,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":23,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":23,"enrollmentInfo":58,"targetDuration":23,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":35,"whyStopped":23,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Minneapolis Heart Institute Foundation","OTHER",[8,14],{"label":9,"type":6,"description":10,"interventionNames":11},"Placebo taken first, drug taken second","The placebo is assigned to the patient first, with the medication taken in the second part of participation.",[12,13],"Drug: Rosuvastatin (Crestor)","Drug: Placebo",{"label":15,"type":6,"description":10,"interventionNames":16},"Drug taken first, then placebo taken second",[12,13],[18,24],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Rosuvastatin (Crestor)","The patient will take 3 28-day packs of placebo and 2 28-day packs of rosuvastatin. The order in which they take the placebo or rosuvastatin will be assigned at random.",[15,9],null,{"type":19,"name":25,"description":21,"armGroupLabels":26,"otherNames":23},"Placebo",[15,9],[28],{"name":29,"role":30,"phone":31,"phoneExt":23,"email":32},"Gretchen Program Director, RDN, CDCES","CONTACT","612-863-3383","Gbenson@mhif.org",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":23},"RECRUITING","Minneapolis","Minnesota","55407","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-93.26384,44.97997,{"lat":45,"lon":44},{"type":48,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100577952","phase-4-desifor-expand-mhif-100577952",false,"NCT06804980","DESIFOR-EXPAND (MHIF)","The DEterminig Statin Intolerance for Rosuvastatin Trial","Inclusion Criteria:\n\n* Adult patients (≥ 21 years old) with a prior history of statin intolerance. Statin intolerance is defined by discontinuation of at least 2 different statin medications due to possible side effects. Patients can participate in the trial while on other lipid-lowering agents, such as ezetimibe and PSCK9 inhibitors, as long as the patient has been on the other lipid lowering therapy and tolerating it well for at least 1 month. For individuals with established ASCVD or multiple ASCVD risk factors, initiation of other lipid lowering therapy prior to participation in DESIFOR is encouraged.\n* 2\\. At least 30 days since discontinued use of a statin\n\nExclusion Criteria:\n\n* Women who are pregnant, nursing or attempting to become pregnant\n* Individuals who experienced severe reactions in the past, including rhabdomyolysis, severe myositis, anaphylaxis\n* Individuals who are not otherwise clinically indicated to take rosuvastatin 20 mg","ALL","21 Years",{"count":59,"type":60},100,"ESTIMATED","INTERVENTIONAL",[63],"PHASE4","The DESIFOR pilot study was conducted to determine the feasibility of utilizing an n-of-1 trial to facilitate tolerance of unblinded rosuvastatin in patients with prior statin intolerance",[66,67,68],"Statin Therapy","Statin Adverse Reaction","Statin",[70,71,72,73],"Statin Intolerance","lipid-lowering medication","LDL","LDL Cholesterol","2025-01-28",{"date":76,"type":77},"2025-02-03","ACTUAL",{"date":79,"type":60},"2025-02-01",{"date":81,"type":60},"2026-12-31",{"name":5,"class":6},1]